Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMJ Open Gastroenterol
Main Authors: Yee, Brittany E, Nguyen, Nghia H, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2016
Teme:
Meta Analysis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780041/
https://ncbi.nlm.nih.gov/pubmed/26966547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2015-000056
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki